Search clinical trials for: tivozanib (AV-951) paclitaxel

Total 56 results

Dana-Farber Cancer Institute
National Comprehensive Cancer Network; AVEO Pharmaceuticals, Inc.

Terminated

Tivozanib As Maintenance Therapy In GYN

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

United States
AVEO Pharmaceuticals, Inc.

Completed

An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States
Massachusetts General Hospital
National Comprehensive Cancer Network

Completed

Tivozanib for Recurrent Glioblastoma

Glioblastoma

United States
Emory University
AVEO Pharmaceuticals, Inc.

Terminated

Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer

Hepatocellular Cancer

United States
AVEO Pharmaceuticals, Inc.

Completed

A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy Subjects

Food Effect of Tivozanib in Health Subjects

United States
AVEO Pharmaceuticals, Inc.

Terminated

A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

Solid Tumors

United States, Canada, Netherlands, India, Russian Federation, Ukraine
AVEO Pharmaceuticals, Inc.

Completed

Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers

Colorectal Cancer | Gastrointestinal Cancer

Netherlands
Roswell Park Cancer Institute
National Cancer Institute (NCI); National Comprehensive Cancer Network; AVEO...

Completed

Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery

Advanced Adult Hepatocellular Carcinoma | Non-Resectable Hepatocellular Carcinoma

United States
Northwestern University
National Comprehensive Cancer Network

Completed

Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (TIVO)

Recurrent Fallopian Tube Cancer | Recurrent Epithelial Ovarian Cancer | Recurrent Primary Peritoneal Cancer

United States
AVEO Pharmaceuticals, Inc.

Completed

A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma

Carcinoma, Renal Cell

Ukraine, India, Russian Federation
Northwestern University
AVEO Pharmaceuticals, Inc.

Completed

A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas

Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma

United States
Roswell Park Cancer Institute
AVEO Pharmaceuticals, Inc.

Withdrawn

Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer

Stage III Renal Cell Cancer | Stage II Renal Cell Cancer
AVEO Pharmaceuticals, Inc.

Completed

A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer

United States, Germany
AVEO Pharmaceuticals, Inc.

Completed

A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (TIVO-1)

Advanced Renal Cell Carcinoma

United States, Argentina, Bulgaria, Canada, Chile, Czechia, France, Hungary, India, Italy, Poland, Romania, Russian Federation, Serbia, Ukraine, United Kingdom
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital and other collaborators

Completed

RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer

Gastrointestinal Cancer

United States
Massachusetts General Hospital
National Comprehensive Cancer Network

Active, not recruiting

Tivozanib + Enzalutamide in Adv Prostate Cancer

Prostate Cancer

United States
AVEO Pharmaceuticals, Inc.

Completed

A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors

Advanced Solid Tumors | Locally Advanced or Metastatic Breast or Colorectal Cancer

United States
AVEO Pharmaceuticals, Inc.
Bristol-Myers Squibb

Completed

Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC

Carcinoma, Renal Cell

France
University of Utah

Withdrawn

A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation

Non-small Cell Lung Cancer | Stage IV Disease | EGFR Unknown or Wild-type
AVEO Pharmaceuticals, Inc.

Completed

A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Institute for Neurodegenerative Disorders

Completed

Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

Alzheimer Disease

United States
Dana-Farber Cancer Institute

Withdrawn

Tivozanib + Gemcitabine in Metastatic RCC

Renal Cell Carcinoma

United States
AVEO Pharmaceuticals, Inc.
Astellas Pharma Inc

Terminated

Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (BATON-BC)

Triple Negative Breast Cancer

Germany, Taiwan, Spain, Ukraine, Australia, Korea, Republic of, Canada, United States, Italy, Bahamas
M.D. Anderson Cancer Center
AVEO Pharmaceuticals, Inc.

Recruiting

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Barbara Parker, MD
Oncternal Therapeutics, Inc

Completed

Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer

Breast Neoplasms

United States
National Cancer Institute (NCI)
National Center for Complementary and Integrative Health (NCCIH); Radiation...

Completed

Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung Cancer | Adenosquamous Cell Lung Cancer

United States
Amgen
Genentech, Inc.

Completed

A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab

Non-Small Cell Lung Cancer
University of Arkansas

Completed

Vaccination of Triple Negative Breast Cancer Patients

Breast Neoplasms | Triple Negative Breast Cancer

United States
Toray Industries, Inc

Recruiting

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

Gastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States, Japan
ImmunityBio, Inc.

Withdrawn

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (TNBC)

Triple Negative Breast Cancer (TNBC)

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Terminated

Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)

Cancer | Solid Tumors

United States
University of Arkansas

Completed

Vaccination of High Risk Breast Cancer Patients

Breast Cancer | Breast Neoplasms

United States
The Affiliated Hospital of the Chinese Academy...

Unknown

Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma (ESCC-307PLAH)

Esophageal Squamous Carcinoma

China
ImmunityBio, Inc.

Active, not recruiting

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Colorectal Cancer Metastatic | mCRC

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

Hepatocellular Carcinoma Non-resectable | Hepatocellular Carcinoma Recurrent

United States
ImmunityBio, Inc.

Unknown

QUILT-3.080: NANT Pancreatic Cancer Vaccine

Pancreatic Cancer

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Merkel Cell Carcinoma
ImmunityBio, Inc.

Active, not recruiting

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Triple Negative Breast Cancer

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Triple Negative Breast Cancer
ImmunityBio, Inc.

Withdrawn

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Melanoma
ImmunityBio, Inc.

Withdrawn

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Metastatic Pancreatic Cancer

United States
Toray Industries, Inc

Recruiting

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Cholangiocarcinoma | Bladder Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer | Palpable Subcutaneous Malignant Lesions

United States, France
Flemming Forsberg
National Cancer Institute (NCI)

Recruiting

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable...

United States, Norway
ImmunityBio, Inc.

Withdrawn

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Urothelial Carcinoma
ImmunityBio, Inc.

Unknown

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Squamous Cell Carcinoma

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Ovarian Cancer
ImmunityBio, Inc.

Withdrawn

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Head and Neck Squamous Cell Carcinoma
ImmunityBio, Inc.

Withdrawn

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Non-small Cell Lung Cancer
ImmunityBio, Inc.

Withdrawn

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Colorectal Cancer

Search clinical trials for: tivozanib (AV-951) paclitaxel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations